Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity

British Journal of Haematology

Volumn 164, Issue 2, 2014, Pages 233-244

  Gandhi, Anita K ^a   Mendy, Derek ^a   Waldman, Michelle ^a   Chen, Gengxin ^a   Rychak, Emily ^a   Miller, Karen ^a   Gaidarova, Svetlana ^a   Ren, Yan ^a   Wang, Maria ^a   Breider, Michael ^a   Carmel, Gilles ^a   Mahmoudi, Afshin ^a   Jackson, Pilgrim ^a   Abbasian, Mahan ^a   Cathers, Brian E ^a   Schafer, Peter H ^a   Daniel, Tom O ^a   Lopez Girona, Antonia ^a   Thakurta, Anjan ^a   Chopra, Rajesh ^a  

^a CELGENE CORPORATION   (United States)

Author keywords

Cereblon; Cullin 4 ring ligase complex; DNA damage binding protein 1; Immunomodulatory drugs; Myeloma

Indexed keywords

BIOLOGICAL MARKER; CARRIER PROTEINS AND BINDING PROTEINS; CEREBLON PROTEIN; LENALIDOMIDE; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CRBN65; POMALIDOMIDE; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ARTICLE; CANCER RESISTANCE; CEREBLON GENE; DRUG RESISTANCE; GENE; GENE EXPRESSION ASSAY; IMMUNOHISTOCHEMISTRY; MULTIPLE MYELOMA; MYELOMA CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; WESTERN BLOTTING;

CEREBLON; CULLIN 4 RING LIGASE COMPLEX; DNA DAMAGE BINDING PROTEIN 1; IMMUNOMODULATORY DRUGS; MYELOMA;

ALTERNATIVE SPLICING; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; MULTIPLE MYELOMA; PEPTIDE HYDROLASES; RNA ISOFORMS; THALIDOMIDE; TUMOR MARKERS, BIOLOGICAL;

EID: 84891629005     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12622     Document Type: Article

References (24)

1. Bakkour, N., Lin, Y., Maire, S., Ayadi, L., Mahuteau-Betzer, F., Nguyen, C.H., Mettling, C., Portales, P., Grierson, D., Chabot, B., Jeanteur, P., Branlant, C., Corbeau, P. & Tazi, J. (2007) Small-molecule inhibition of HIV pre-mRNA splicing as a novel antiretroviral therapy to overcome drug resistance. PLoS Pathogens, 3, e159.
2. Broyl, A., Kuiper, R., van Duin, M., van der Holt, B., el Jarari, L., Bertsch, U., Zweegman, S., Buijs, A., Hose, D., Lokhorst, H.M., Goldschmidt, H. & Sonneveld, P. (2013) High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood, 121, 624-627.
3. Chapman, M.A., Lawrence, M.S., Keats, J.J., Cibulskis, K., Sougnez, C., Schinzel, A.C., Harview, C.L., Brunet, J.P., Ahmann, G.J., Adli, M., Anderson, K.C., Ardlie, K.G., Auclair, D., Baker, A., Bergsagel, P.L., Bernstein, B.E., Drier, Y., Fonseca, R., Gabriel, S.B., Hofmeister, C.C., Jagannath, S., Jakubowiak, A.J., Krishnan, A., Levy, J., Liefeld, T., Lonial, S., Mahan, S., Mfuko, B., Monti, S., Perkins, L.M., Onofrio, R., Pugh, T.J., Rajkumar, S.V., Ramos, A.H., Siegel, D.S., Sivachenko, A., Stewart, A.K., Trudel, S., Vij, R., Voet, D., Winckler, W., Zimmerman, T., Carpten, J., Trent, J., Hahn, W.C., Garraway, L.A., Meyerson, M., Lander, E.S., Getz, G. & Golub, T.R. (2011) Initial genome sequencing and analysis of multiple myeloma. Nature, 471, 467-472.
4. Flicek, P., Amode, M.R., Barrell, D., Beal, K., Brent, S., Carvalho-Silva, D., Clapham, P., Coates, G., Fairley, S., Fitzgerald, S., Gil, L., Gordon, L., Hendrix, M., Hourlier, T., Johnson, N., Kähäri, A.K., Keefe, D., Keenan, S., Kinsella, R., Komorowska, M., Koscielny, G., Kulesha, E., Larsson, P., Longden, I., McLaren, W., Muffato, M., Overduin, B., Pignatelli, M., Pritchard, B., Riat, H.S., Ritchie, G.R.S., Ruffier, M., Schuster, M., Sobral, D., Tang, Y.A., Taylor, K., Trevanion, S., Vandrovcova, J., White, S., Wilson, M., Wilder, S.P., Aken, B.L., Birney, E., Cunningham, F., Dunham, I., Durbin, R., Fernández-Suarez, X.M., Harrow, J., Herrero, J., Hubbard, T.J.P., Parker, A., Proctor, G., Spudich, G., Vogel, J., Yates, A., Zadissa, A. & Searle, S.M.J. (2012) Ensembl 2012. Nucleic Acids Research, 40, D84-D90.
5. Gandhi, A.K., Lentzsch, S., Schey, S.A., Calle, Y., Chelliah, R., Orlowski, R.Z., Bjorklund, C., Madan, A., Waldman, M., Ning, Y., Mendy, D., Lopez-Girona, A., Schafer, P., Aukerman, L., Thakurta, A. & Chopra, R. (2013) Exon mutations in cereblon (CRBN) and DNA damage binding protein 1 (DDB1) genes are rare in myeloma cells and patients. Clinical Lymphoma Myeloma and Leukemia, 13, S182-S183.
6. Groisman, R., Polanowska, J., Kuraoka, I., Sawada, J., Saijo, M., Drapkin, R., Kisselev, A.F., Tanaka, K. & Nakatani, Y. (2003) The ubiquitin ligase activity in the DDB2 and CSA complexes is differentially regulated by the COP9 signalosome in response to DNA damage. Cell, 113, 357-367.
7. Heintel, D., Rocci, A., Ludwig, H., Bolomsky, A., Caltagirone, S., Schreder, M., Pfeifer, S., Gisslinger, H., Zojer, N., Jäger, U. & Palumbo, A. (2013) High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. British Journal of Haematology, 161, 695-700.
8. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. (1995) Guidelines for industry: text on validation of analytical procedures. http://www.labcompliance.de/documents/international/ich/h-307-ich-fda-methods-terminology-ichq2a.pdf. Accessed September 9, 2013.
9. Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y. & Handa, H. (2010) Identification of a primary target of thalidomide teratogenicity. Science (New York, N.Y.), 327, 1345-1350.
10. Klimowicz, A., Neri, P., Belch, A., Belch, A., Dean, M., Ren, L., Gratton, K., Slaby, J., Johnson, J., Duggan, P., Steward, D.A. & Bahlis, N.J. (2012) High cereblon protein expression correlates with improved response and survival in myeloma patients treated with lenalidomide. Blood, 120, 931.
11. Lasho, T.L., Finke, C.M., Hanson, C.A., Jimma, T., Knudson, R.A., Ketterling, R.P., Pardanani, A. & Tefferi, A. (2012) SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients. Leukemia, 26, 1135-1137.
12. Lee, T., Ma, W., Zhang, X., Giles, F., Cortes, J., Kantarjian, H. & Albitar, M. (2008) BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations. Molecular Cancer Therapeutics, 7, 3834-3841.
13. Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A.K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., Mahmoudi, A., Cathers, B., Rychak, E., Gaidarova, S., Chen, R., Schafer, P.H., Handa, H., Daniel, T.O., Evans, J.F. & Chopra, R. (2012) Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia, 26, 2326-2335.
14. Moalli, P.A., Pillay, S., Krett, N.L. & Rosen, S.T. (1993) Alternatively spliced glucocorticoid recep-tor messenger RNAs in glucocorticoid-resistant human multiple myeloma cells. Cancer Research, 53, 3877-3879.
15. Munshi, N.C., Li, C., Minvielle, S., Moreau, P., Amin, S., Magrangeas, M., Anderson, K. & Avetloiseau, H. (2009) Use of alternate splicing to identify subgroups in uniformly treated newly-diagnosed myeloma. Journal of Clinical Oncology, 27, 8602.
16. National Cancer Institute Division of Cancer Prevention. (1999) Requirements for pharmacokinetic and biomarker methods development. http://prevention.cancer.gov/files/clinical-trials/biomarkers.pdf. Accessed September 9, 2013.
17. Ovsyannikova, I.G., Kennedy, R.B., O'Byrne, M., Jacobson, R.M., Pankratz, V.S. & Poland, G.A. (2012) Genome-wide association study of antibody response to smallpox vaccine. Vaccine, 30, 4182-4189.
18. Papaemmanuil, E., Cazzola, M., Boultwood, J., Malcovati, L., Vyas, P., Bowen, D., Pellagatti, A., Wainscoat, J.S., Hellstrom-Lindberg, E., Gambacorti-Passerini, C., Godfrey, A.L., Rapado, I., Cvejic, A., Rance, R., McGee, C., Ellis, P., Mudie, L.J., Stephens, P.J., McLaren, S., Massie, C.E., Tarpey, P.S., Varela, I., Nik-Zainal, S., Davies, H.R., Shlien, A., Jones, D., Raine, K., Hinton, J., Butler, A.P., Teague, J.W., Baxter, E.J., Score, J., Galli, A., Della Porta, M.G., Travaglino, E., Groves, M., Tauro, S., Munshi, N.C., Anderson, K.C., El-Naggar, A., Fischer, A., Mustonen, V., Warren, A.J., Cross, N.C., Green, A.R., Futreal, P.A., Stratton, M.R., Campbell, P.J. & Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium (2011) Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. The New England Journal of Medicine, 365, 1384-1395.
19. Rossi, D., Bruscaggin, A., Spina, V., Rasi, S., Khiabanian, H., Messina, M., Fangazio, M., Vaisitti, T., Monti, S., Chiaretti, S., Guarini, A., Del Giudice, I., Cerri, M., Cresta, S., Deambrogi, C., Gargiulo, E., Gattei, V., Forconi, F., Bertoni, F., Deaglio, S., Rabadan, R., Pasqualucci, L., Foa, R., Dalla-Favera, R. & Gaidano, G. (2011) Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood, 118, 6904-6908.
20. San Miguel, J.S., Weisel, K., Moreau, P., Lacy, M., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Banos, A., Oriol, A., Alegre, A., Chen, C., Cavo, M., Garderet, L., Ivanova, V., Martinez-Lopez, J., Belch, A., Palumbo, A., Schey, S., Sonneveld, P., Yu, X., Sternas, L., Jacques, C., Zaki, M. & Dimopoulos, M. (2013) Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. The Lancet Oncology, 14, 1055-1066.
21. Schuster, S.R., Kortum, K.M., Zhu, Y.X., Braggio, E., Shi, C.-X., Bruins, L.A., Schmidt, J.E., Ahmann, G.J., Kumar, S., Rajikumar, V., Mikhael, J., Roy, V., LaPlant, B., Laumann, K., Barlogie, B., Shaughnessy, J., Fonseca, R., Bergsagel, P.L., Lacy, M. & Stewart, A.K. (2012) Cereblon expression predicts response, progression free and overall survival after pomalidomide and dexamethasone therapy in multiple myeloma (oral presentation). Blood (ASH Annual Meeting Abstracts), 120, 194.
22. Wang, L., Lawrence, M.S., Wan, Y., Stojanov, P., Sougnez, C., Stevenson, K., Werner, L., Sivachenko, A., DeLuca, D.S., Zhang, L., Zhang, W., Vartanov, A.R., Fernandes, S.M., Goldstein, N.R., Folco, E.G., Cibulskis, K., Tesar, B., Sievers, Q.L., Shefler, E., Gabriel, S., Hacohen, N., Reed, R., Meyerson, M., Golub, T.R., Lander, E.S., Neuberg, D., Brown, J.R., Getz, G. & Wu, C.J. (2011) SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. The New England Journal of Medicine, 365, 2497-2506.
23. Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., Chalkidis, G., Suzuki, Y., Shiosaka, M., Kawahata, R., Yamaguchi, T., Otsu, M., Obara, N., Sakata-Yanagimoto, M., Ishiyama, K., Mori, H., Nolte, F., Hofmann, W.K., Miyawaki, S., Sugano, S., Haferlach, C., Koeffler, H.P., Shih, L.Y., Haferlach, T., Chiba, S., Nakauchi, H., Miyano, S. & Ogawa, S. (2011) Frequent pathway mutations of splicing machinery in myelodysplasia. Nature, 478, 64-69.
24. Zhu, Y.X., Braggio, E., Shi, C., Bruins, L.A., Schmidt, J.E., Van Wier, S., Chang, X., Bjorklund, C.C., Fonseca, R., Bergsagel, P.L., Orlowski, R.Z. & Stewart, A.K. (2011) Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood, 118, 4771-4779.